Product Code: RP-ID-10325690 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10325690
Market Overview:
Asia Pacific Active Pharmaceutical Ingredients (API) Market 2020-2026 by Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application, Drug Type, and Country: Trend Forecast and Growth Opportunity
Asia Pacific active pharmaceutical ingredients (API) market will grow by 9.1% annually with a total addressable market cap of $584.2 billion over 2020-2030 amid the COVID-19 pandemic.
Highlighted with 38 tables and 65 figures, this 133-page report “Asia Pacific Active Pharmaceutical Ingredients (API) Market 2020-2026 by Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application, Drug Type, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific API market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2026 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific API market in every aspect of the classification from perspectives of Synthesis, Manufacturing Process, Therapeutic Application, Drug Type, and Country.
Based on Synthesis, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2015-2026 included in each section.
Synthetic API
• Branded Synthetic API
• Generic Synthetic API
Biotech API by Drug Type:
• Monoclonal Antibodies
• Recombinant Proteins
• Vaccines
• Other Biotech APIs
Biotech API by Customer Base:
• Innovative Biologic API
• Generic Biosimilar API
Biotech API by Expression Technology:
• Mammalian Expression
• Microbial Expression
• Yeast Expression
• Insect Expression
• Other Expression Technologies
HPAPI
• Branded HPAPI
• Generic HPAPI
Based on Manufacturing Process, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2015-2026 included in each section.
Captive Manufacturing
• Branded Captive API
• Generic Captive API
Merchant Manufacturing by Drug Type:
• Branded Merchant API
• Generic Merchant API
Merchant Manufacturing by Drug Synthesis:
• Merchant Synthetic API
• Merchant Biotech API
Based on Therapeutic Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2015-2026 included in each section.
• Infectious Diseases
• Oncology
• Ophthalmology
• Cardiovascular Disorders
• Central Nervous System
• Pulmonary Disorders
• Orthopedics
• Other Applications
Based on Drug Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2015-2026 included in each section.
• Branded Prescription Drugs
• Generic Prescription Drugs
• OTC Drugs
Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
For each aforementioned country, detailed analysis and data for annual revenue are available for 2015-2026. The breakdown of key national markets by Synthesis, Manufacturing Process, and Therapeutic Application over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Asia Pacific API market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
AbbVie Inc.
Astrazeneca
Aurobindo Pharma Ltd.
Bayer Healthcare
Bioniche Animal Health
Boehringer Ingelheim
Bristol-Myers Squibb
Ceva Animal Health, Inc.
Elanco Animal Health
Eli Lilly and Company
F. Hoffmann-La Roche
Glaxosmithkline PLC
Heska Co.
Lonza Group
Merck & Co., Inc.
Novartis International AG
Pfizer, Inc.
Ranbaxy Laboratories
Sanofi
Sun Pharmaceutical Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
AbbVie Inc.
Astrazeneca
Aurobindo Pharma Ltd.
Bayer Healthcare
Bioniche Animal Health
Boehringer Ingelheim
Bristol-Myers Squibb
Ceva Animal Health, Inc.
Elanco Animal Health
Eli Lilly and Company
F. Hoffmann-La Roche
Glaxosmithkline PLC
Heska Co.
Lonza Group
Merck & Co., Inc.
Novartis International AG
Pfizer, Inc.
Ranbaxy Laboratories
Sanofi
Sun Pharmaceutical Industries Ltd.
Related Reports
Proof of Quality & Reliability
